ArticleJGH open : an open access journal of gastroenterology and hepatology2022

Comparative study between sorafenib and lenvatinib as the first-line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real-world setting.

Taito Fukushima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.